NUCLIDIUM and Guerbet (GBT) announced a strategic partnership to advance NUCLIDIUM?s diagnostic and therapeutic copper-based radiopharmaceuticals. This partnership will provide NUCLIDIUM access to Guerbet?s knowledge and extensive network in diagnostic imaging, manufacturing, and clinical trials, aiding the progression of NUCLIDIUM?s theranostic candidates towards commercialization. Guerbet has made a strategic, non-exclusive investment in NUCLIDIUM as part of the agreement.

As part of the agreement, François Nicolas, Senior Vice President of R&D at Guerbet, will join NUCLIDIUM?s Board of Directors as an observer. NUCLIDIUM is advancing a unique pipeline of targeted copper-based radiopharmaceuticals leveraging isotopes 61Cu and 67Cu. Its innovative platform facilitates a seamless transition from diagnostic to therapeutic applications by merely exchanging the isotopes on the same tumor-targeting molecule.

The company will apply its easy-to-produce manufacturing process to enhance product availability and address major challenges in radiotheranostic medicine to develop precise and effective theranostics for multiple solid tumor types including prostate, colorectal, gastric, breast and pancreatic cancers as well as neuroendocrine tumors. The partnership with Guerbet is a critical pillar in NUCLIDIUM?s strategy to establish valuable collaborations to advance its proprietary pipeline and ensure reliable supply chains for its copper-based radiopharmaceuticals.